Bio Vitos

PRESSRELEASE

Bio Vitos Ltd – Capital Raising in England and the Next Step Towards Listing

Dear Shareholders,

Bio Vitos Ltd is now entering the next phase of its development. We are currently raising capital in England through established UK brokers at an offering price of £1.50 per share (SEK 19.35).

The company's development continues to be very positive.

The FE-MININ Study is progressing according to plan, and participant interest has significantly exceeded our original expectations.

This further strengthens our confidence in the commercial potential of SUCCIFER as a future treatment for iron deficiency.

Our primary focus is healthy women and men suffering from iron and nutritional deficiencies—a patient population comprising hundreds of millions of people worldwide.

Iron deficiency is the world's most common nutritional deficiency, affecting an estimated two billion people globally.

The global market for iron deficiency treatments is worth the equivalent of hundreds of billions of GBP annually and is expected to continue growing over the coming years.

If SUCCIFER proves to provide an effective oral treatment with good tolerability and without the side effects commonly associated with traditional iron supplements, we believe the product has the potential to address a substantial international market opportunity.

Based on this progress, I, as the Company's largest shareholder, will make a limited number of my shares available for sale at £2.00 per share (SEK 25.88).

This reflects my personal assessment of the value of Bio Vitos Ltd, the progress we are making, and the market position I believe the Company has the opportunity to achieve in the years ahead.

Today, the full Board of Directors of Bio Vitos Ltd will be appointed, and the Company's shareholder register has now been officially registered with Companies House.

The next step is to commence trading in the Company's shares, which is expected to begin within the coming days.

Our target market price is £2.00 per share (SEK 25.88). The previously announced minimum price of £1.50 per share (SEK 19.35) will remain in effect for the next twelve months. In addition, the Company's largest shareholders, who collectively control more than 60% of Bio Vitos Ltd, have confirmed that they do not intend to sell any of their shares below £2.00 per share (SEK 25.88).

We are moving forward with full commitment and look forward to an exciting autumn with continued progress in our clinical programs, the ongoing capital raising in England, and the commencement of trading in Bio Vitos Ltd shares.

Kind regards,

BORD OF DIRECTORS BIO VITOS LTD

Largest Shareholder of the Board